An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...
PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for ...
MethylScan is a low-cost blood test that detects multiple cancers and liver diseases by analyzing DNA methylation patterns ...
A recent study published in Cell Reports Medicine has identified distinct microbial signatures within the oral cavity and gut ...
The United States Food and Drug Administration (FDA) issued guidance on its “Breakthrough Devices Program” in 2023. The ...
Prostate cancer remains one of the most common diseases among men, yet current screening methods often lead to unnecessary ...
An artificial intelligence (AI) model developed by researchers at The University of Texas MD Anderson Cancer Center ...
MethylScan is a low-cost blood test that detects cancers and organ diseases by analyzing DNA methylation, improving early diagnosis, and identifying disease origin.
How does preventing cirrhosis lower the risk of liver cancer mortality? Early intervention, viral hepatitis treatment, and ...
TOBY, Inc., a biotechnology company developing non-invasive cancer screening technologies, today announced that the U.S. Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results